Company Statements

Biocon Biologics  /  Company Statements

Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.

  • Posted by: Biocon Biologics

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab

Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab
  • Posted by: Biocon Biologics

Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart

  • Posted by: Biocon Biologics

Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart

  • Posted by: Biocon Biologics

Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020

  • Posted by: Biocon Biologics

Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart

Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart
  • Posted by: Biocon Biologics

Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification

  • Posted by: Biocon Biologics

Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed

  • Posted by: Biocon Biologics

Biocon’s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed

  • Posted by: Biocon Biologics

Biocon’s Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection

  • Posted by: Biocon Biologics
Share
buy twitter followers